Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells

A critical problem in leukemia as well as other cancer therapies is the development of chemotherapeutic drug-resistance. We have developed models of hematopoietic drug resistance that are based on expression of dominant-negative TP53 [TP53 (DN)] or constitutively-active MEK1 [MEK1(CA)] oncogenes in...

Descripción completa

Detalles Bibliográficos
Autores principales: Abrams, Stephen L., Ruvolo, Peter P., Ruvolo, Vivian R., Ligresti, Giovanni, Martelli, Alberto M., Cocco, Lucio, Ratti, Stefano, Tafuri, Agostino, Steelman, Linda S., Candido, Saverio, Libra, Massimo, McCubrey, James A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652725/
https://www.ncbi.nlm.nih.gov/pubmed/29100331
http://dx.doi.org/10.18632/oncotarget.20408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652725/
https://www.ncbi.nlm.nih.gov/pubmed/29100331
http://dx.doi.org/10.18632/oncotarget.20408

Ejemplares similares